Abstract
Two phase 3 trials reported a prolonged survival in the third-line setting of colorectal cancer patients treated with regorafenib with the longest duration of treatment of 16 months. Herein, we reported a unique case of a patient refractory to conventional chemotherapy who showed a prolonged stable disease with regorafenib.
Original language | English |
---|---|
Pages (from-to) | 2379-2383 |
Number of pages | 5 |
Journal | Clinical Case Reports |
Volume | 7 |
Issue number | 12 |
DOIs | |
Publication status | Published - Dec 1 2019 |
Keywords
- colorectal cancer
- long-term survival
- regorafenib
ASJC Scopus subject areas
- Medicine(all)